Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the … MJ Rybak, J Le, TP Lodise, DP Levine, JS Bradley, C Liu, BA Mueller, ... American Journal of Health-System Pharmacy 77 (11), 835-864, 2020 | 1218 | 2020 |
High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity LK Hidayat, DI Hsu, R Quist, KA Shriner, A Wong-Beringer Archives of internal medicine 166 (19), 2138-2144, 2006 | 1100 | 2006 |
Lipid formulations of amphotericin B: clinical efficacy and toxicities A Wong-Beringer, RA Jacobs, BJ Guglielmo Clinical Infectious Diseases 27 (3), 603-618, 1998 | 527 | 1998 |
Regulatory oversight and safety of probiotic use V Venugopalan, KA Shriner, A Wong-Beringer Emerging infectious diseases 16 (11), 1661, 2010 | 273 | 2010 |
Vancomycin-associated nephrotoxicity: a critical appraisal of risk with high-dose therapy A Wong-Beringer, J Joo, E Tse, P Beringer International journal of antimicrobial agents 37 (2), 95-101, 2011 | 221 | 2011 |
Comparison of method-specific vancomycin minimum inhibitory concentration values and their predictability for treatment outcome of meticillin-resistant Staphylococcus aureus … DI Hsu, LK Hidayat, R Quist, J Hindler, A Karlsson, A Yusof, ... International journal of antimicrobial agents 32 (5), 378-385, 2008 | 205 | 2008 |
Use of an efflux pump inhibitor to determine the prevalence of efflux pump-mediated fluoroquinolone resistance and multidrug resistance in Pseudomonas aeruginosa J Kriengkauykiat, E Porter, O Lomovskaya, A Wong-Beringer Antimicrobial agents and chemotherapy 49 (2), 565-570, 2005 | 190 | 2005 |
Molecular Correlation for the Treatment Outcomes in Bloodstream Infections Caused by Escherichia coli and Klebsiella pneumoniae with Reduced Susceptibility … A Wong-Beringer, J Hindler, M Loeloff, AM Queenan, N Lee, DA Pegues, ... Clinical infectious diseases 34 (2), 135-146, 2002 | 181 | 2002 |
Defining the Breakpoint Duration of Staphylococcus aureus Bacteremia Predictive of Poor Outcomes E Minejima, N Mai, N Bui, M Mert, WJ Mack, RC She, P Nieberg, ... Clinical Infectious Diseases 70 (4), 566-573, 2020 | 137 | 2020 |
Applying new diagnostic criteria for acute kidney injury to facilitate early identification of nephrotoxicity in vancomycin-treated patients E Minejima, J Choi, P Beringer, M Lou, E Tse, A Wong-Beringer Antimicrobial agents and chemotherapy 55 (7), 3278-3283, 2011 | 134 | 2011 |
Fluoroquinolone-resistant Pseudomonas aeruginosa: risk factors for acquisition and impact on outcomes DI Hsu, MP Okamoto, R Murthy, A Wong-Beringer Journal of Antimicrobial Chemotherapy 55 (4), 535-541, 2005 | 119 | 2005 |
Comparison of type III secretion system virulence among fluoroquinolone-susceptible and-resistant clinical isolates of Pseudomonas aeruginosa A Wong-Beringer, J Wiener-Kronish, S Lynch, J Flanagan Clinical microbiology and infection 14 (4), 330-336, 2008 | 115 | 2008 |
Therapeutic Challenges Associated with Extended‐Spectrum, β‐Lactamase‐Producing Escherichia coli and Klebsiella pneumoniae A Wong‐Beringer Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 21 (5 …, 2001 | 110 | 2001 |
Differentiation in Quinolone Resistance by Virulence Genotype in Pseudomonas aeruginosa M Agnello, A Wong-Beringer Public Library of Science 7 (8), e42973, 2012 | 109 | 2012 |
Executive Summary: Therapeutic Monitoring of Vancomycin for Serious Methicillin-Resistant Staphylococcus aureus Infections: A Revised Consensus Guideline … MJ Rybak, J Le, T Lodise, D Levine, J Bradley, C Liu, B Mueller, M Pai, ... Journal of the Pediatric Infectious Diseases Society 9 (3), 281-284, 2020 | 108 | 2020 |
Systemic antifungal therapy: new options, new challenges A Wong‐Beringer, J Kriengkauykiat Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 23 (11 …, 2003 | 103 | 2003 |
Economic aspects of antibacterial adverse effects PM Beringer, A Wong-Beringer, JP Rho Pharmacoeconomics 13, 35-49, 1998 | 97 | 1998 |
Wavelength-normalized spectroscopic analysis of Staphylococcus aureus and Pseudomonas aeruginosa growth rates SE McBirney, K Trinh, A Wong-Beringer, AM Armani Biomedical optics express 7 (10), 4034-4042, 2016 | 96 | 2016 |
Immune globulin therapy in allogeneic bone marrow transplant: a critical review. BJ Guglielmo, A Wong-Beringer, CA Linker Bone marrow transplantation 13 (5), 499-510, 1994 | 94 | 1994 |
Activity of ceftolozane-tazobactam and ceftazidime-avibactam against beta-lactam-resistant Pseudomonas aeruginosa isolates RM Humphries, JA Hindler, A Wong-Beringer, SA Miller Antimicrobial agents and chemotherapy 61 (12), 10.1128/aac. 01858-17, 2017 | 91 | 2017 |